Company Quick10K Filing
Quick10K
Lazuriton Nano Biotechnology
10-Q 2019-06-30 Quarter: 2019-06-30
10-Q 2019-03-31 Quarter: 2019-03-31
10-K 2018-12-31 Annual: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-06-30 Quarter: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-K 2017-12-31 Annual: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
10-Q 2017-06-30 Quarter: 2017-06-30
10-Q 2017-03-31 Quarter: 2017-03-31
10-K 2016-12-31 Annual: 2016-12-31
10-Q 2016-09-30 Quarter: 2016-09-30
10-Q 2016-06-30 Quarter: 2016-06-30
8-K 2019-06-24 Officers
CQH Cheniere Energy Partners Holdings 6,956
EDR Education Realty Trust 3,375
NGTF NightFood 23
CETY Clean Energy Technologies 17
LEAI Legacy Education Alliance 9
GNTW Globe Net Wireless 0
ZVVT ZEV Ventures 0
CGND China Grand Resorts 0
MWF MWF Global 0
RKFL B4MC Gold Mines 0
LNBI 2019-06-30
Part I - Financial Information
Item 1. Financial Statements
Note 1. Nature of Operations and Summary of Accounting Policies
Note 2. Accrued Expenses
Note 3. Due To Related Parties
Note 4. Income Taxes
Note 5. Subsequent Event
Item 2. Management S Discussion and Analysis of Financial Condition and Results of Operation.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Item 4. Controls and Procedures.
Part II - Other Information
Item 1. Legal Proceedings.
Item 1A. Risk Factors.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Item 3. Defaults Upon Senior Securities.
Item 4. Mine Safety Disclosures.
Item 5. Other Information.
Item 6. Exhibits.
EX-31.1 lznn_ex311.htm
EX-31.2 lznn_ex312.htm
EX-32.1 lznn_ex321.htm
EX-32.2 lznn_322.htm

Lazuriton Nano Biotechnology Earnings 2019-06-30

LNBI 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

10-Q 1 lznn_10q.htm FORM 10-Q lznn_10q.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

 

x

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED June 30, 2019

¨

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

FOR THE TRANSITION PERIOD FROM _____________ TO _____________

 

COMMISSION FILE NUMBER 333-210091

 

Lazuriton Nano Biotechnology (U.S.A.) Inc.

(Exact name of registrant as specified in its charter)

 

Nevada

37-1786808

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

341, Sec. 2, Wanshou Road, 10th Floor

Guishan District, Taoyuan City, 333, Taiwan (Republic of China)

(Address of principal executive offices, Zip Code)

 

011-886-3-329-5585

(Registrant’s telephone number, including area code)

 

___________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ¨ No x

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such fi les). Yes ¨ No x

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non- accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

¨

Accelerated filer

¨

Non-accelerated filer

x

Smaller reporting company

x

Emerging growth company

x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes x No ¨

 

The number of shares of registrant’s common stock outstanding, as of August 16, 2019 is 100,000,000.

 

 
 
 
 

 

TABLE OF CONTENTS

 

Page

Item 1.

Financial Statements

3

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

10

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

12

Item 4.

Controls and Procedures

12

 

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings

13

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

13

Item 3.

Defaults Upon Senior Securities

13

Item 4.

Mine Safety Disclosures

13

Item 5.

Other Information

13

Item 6.

Exhibits

14

SIGNATURES

15

 

 
2
 
Table of Contents

 

 

PART I - FINANCIAL INFORMATION

 

 ITEM 1. FINANCIAL STATEMENTS

 

LAZURITON NANO BIOTECHNOLOGY (U.S.A.) INC

BALANCE SHEETS

 

 

 

June 30,

2019

 

 

December 31,

2018

 

 

 

(Unaudited)

 

 

 

 

Assets

Current Assets

 

 

 

 

 

 

Cash and cash equivalents

 

$1,347

 

 

$1,197

 

Prepaid expenses

 

 

-

 

 

 

922

 

Total Current Assets

 

 

1,347

 

 

 

2,119

 

 

 

 

 

 

 

 

 

 

Total Assets

 

$1,347

 

 

$2,119

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Deficit

 

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

Accrued expenses

 

$19,554

 

 

$15,086

 

Due to related parties

 

 

213,634

 

 

 

183,794

 

Total Current Liabilities

 

 

233,188

 

 

 

198,880

 

 

 

 

 

 

 

 

 

 

Total Liabilities

 

 

233,188

 

 

 

198,880

 

 

 

 

 

 

 

 

 

 

Stockholders' Deficit

 

 

 

 

 

 

 

 

Common stock, $0.0001 par value; 750,000,000 shares authorized, 100,000,000 shares issued and outstanding

 

 

10,000

 

 

 

10,000

 

Additional paid-in capital

 

 

250,000

 

 

 

250,000

 

Accumulated deficits

 

 

(491,841)

 

 

(456,761)

Total Stockholders' Deficit

 

 

(231,841)

 

 

(196,761)

 

 

 

 

 

 

 

 

 

Total Liabilities and Stockholders' Deficit

 

$1,347

 

 

$2,119

 

 

The accompanying notes to financial statements are an integral part of these statements.

 

 
3
 
Table of Contents

  

LAZURITON NANO BIOTECHNOLOGY (U.S.A.) INC.

STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2019 AND 2018

(UNAUDITED)

 

 

 

Three Months 

Ended 
June 30,
2019

 

 

Three Months 
Ended 
June 30, 
2018

 

 

Six Months
Ended
June 30,
2019

 

 

Six Months

Ended

June 30,

2018

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative expenses

 

 

14,473

 

 

 

18,288

 

 

 

35,080

 

 

 

48,234

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(14,473)

 

 

(18,288)

 

 

(35,080)

 

 

(48,234)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

-

 

 

 

2

 

 

 

-

 

 

 

2

 

Total other income

 

 

-

 

 

 

2

 

 

 

-

 

 

 

2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before income tax

 

 

(14,473)

 

 

(18,286)

 

 

(35,080)

 

 

(48,232)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Provision for income tax

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net loss

 

$(14,473)

 

$(18,286)

 

$(35,080)

 

$(48,232)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

$(0.00)

 

$(0.00)

 

$(0.00)

 

$(0.00)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Shares Outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

 

100,000,000

 

 

 

100,000,000

 

 

 

100,000,000

 

 

 

100,000,000

 

 

The accompanying notes to financial statements are an integral part of these statements.

 

 
4
 
Table of Contents

 

LAZURITON NANO BIOTECHNOLOGY (U.S.A.) INC.

STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2019 AND 2018
(UNAUDITED)

 

 

 

Six Months

Ended

June 30,

2019

 

 

Six Months

Ended

June 30,

2018

 

 

 

 

 

 

 

 

Cash Flows from Operating Activities

 

 

 

 

 

 

Net loss

 

$(35,080)

 

$(48,232)

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Decrease in prepaid expenses

 

 

922

 

 

 

-

 

Increase (decrease) in accrued expenses

 

 

4,468

 

 

 

(1,940)

Increase in due to related parties

 

 

29,840

 

 

 

50,174

 

Net cash provided by operating activities

 

 

150

 

 

 

2

 

 

 

 

 

 

 

 

 

 

Net increase in cash and cash equivalents

 

 

150

 

 

 

2

 

 

 

 

 

 

 

 

 

 

Cash and Cash Equivalents

 

 

 

 

 

 

 

 

Beginning

 

 

1,197

 

 

 

1,193

 

Ending

 

$1,347

 

 

$1,193

 

 

 

 

 

 

 

 

 

 

Supplemental Disclosure of Cash Flows

 

 

 

 

 

 

 

 

Cash paid during the year for:

 

 

 

 

 

 

 

 

Interest expenses

 

$-

 

 

$-

 

Income taxes

 

$-

 

 

$-

 

 

The accompanying notes to financial statements are an integral part of these statements.

 

 
5
 
Table of Contents

  

LAZURITON NANO BIOTECHNOLOGY (U.S.A.) INC.

STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT

(UNAUDITED)

 

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2019

 

 

 

 

 

 

 

Additional

 

 

 

 

 

 

 

Common Stock

 

 

Paid-in

 

 

Accumulated

 

 

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Total

 

Balance at December 31, 2018

 

 

100,000,000

 

 

$10,000

 

 

$250,000

 

 

$(456,761)

 

$(196,761)

Net loss for period ended March 31, 2019

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(20,607)

 

 

(20,607)

Balance at March 31, 2019

 

 

100,000,000

 

 

$10,000

 

 

$250,000

 

 

$(477,368)

 

$(217,368)

Net loss for the period ended June 30, 2019

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(14,473)

 

 

(14,473)

Balance at June 30, 2019

 

 

100,000,000

 

 

$10,000

 

 

$250,000

 

 

$(491,841)

 

$(231,841)

 

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018

 

 

 

 

 

 

 

Additional

 

 

 

 

 

 

 

Common Stock

 

 

Paid-in

 

 

Accumulated

 

 

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Total

 

Balance at December 31, 2017

 

 

100,000,000

 

 

$10,000

 

 

$250,000

 

 

$(364,239)

 

$(104,239)

Net loss for period ended March 31, 2018

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(29,946)

 

 

(29,946)

Balance at March 31, 2018

 

 

100,000,000

 

 

$10,000

 

 

$250,000

 

 

$(394,185)

 

$(134,185)

Net loss for the period ended June 30, 2018

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(18,286)

 

 

(18,286)

Balance at June 30, 2018

 

 

100,000,000

 

 

$10,000

 

 

$250,000

 

 

$(412,471)

 

$(152,471)

 

The accompanying notes to financial statements are an integral part of these statements.

 

 
6
 
Table of Contents

 

LAZURITON NANO BIOTECHNOLOGY (U.S.A.) INC.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2019

 

NOTE 1. NATURE OF OPERATIONS AND SUMMARY OF ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial reporting and in accordance with instructions for Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the unaudited financial statements contained in this report reflect all adjustments that are normal and recurring in nature and considered necessary for a fair presentation of the financial position and the results of operations for the interim periods presented. The year-end balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. The results of operations for the interim period are not necessarily indicative of the results expected for the full year. These unaudited financial statements, footnote disclosures, and other information should be read in conjunction with the financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

 

Organization

 

Lazuriton Nano Biotechnology (U.S.A.) Inc., a company in the developmental stage (the “Company”), was incorporated on June 2, 2015 in the State of Nevada. The Company has conducted limited business operations and had no revenues from operations since its inception. The Company’s business plan is to market and distribute Nano fertilizers products.

 

Going Concern

 

These financial statements were prepared on the basis of accounting principles applicable to going concern, which assumes the realization of assets and discharge of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has incurred net loss of $35,080 and $48,232 for the six months ended June 30, 2019 and 2018, respectively, and had accumulated deficits of $491,841 and $456,761 as of June 30, 2019 and December 31, 2018, respectively, and it had no revenue from operations.

 

The Company faces all the risks common to companies at development stage, including capitalization and uncertainty of funding sources, high initial expenditure levels, uncertain revenue streams, and difficulties in managing growth. The Company's losses raise substantial doubt about its ability to continue as a going concern. The Company's financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.

 

The Company is currently addressing its liquidity issue by continually seeking additional funds through private placements of its securities and/or capital contributions and loans by Chih-Yuan Hsiao, the President and a member of the board of directors. The Company believes its current and future plans enable it to continue as a going concern. The Company's ability to achieve these objectives cannot be determined at this time, however. If we are unable to obtain additional financing, we may be required to reduce the scope of our business development activities, which could harm our business plans, financial condition and operating results. Additional funding may not be available on favorable terms, if at all. These financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts which may differ from those in the accompanying consolidated financial statements.

 

Use of Estimates

 

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the amount of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. However, actual results could differ materially from those results.

 

Classification

 

Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.

 

 
7
 
Table of Contents

  

Cash and Cash Equivalents

 

Cash and cash equivalents include cash and all highly liquid instruments with original maturities of three months or less.

 

Net Loss Per Share

 

Basic income (loss) per share is computed by dividing net income by weighted average number of shares of common stock outstanding during each period. Diluted income per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. At June 30, 2019 and December 31, 2018, the Company does not have any outstanding common stock equivalents; therefore, a separate computation of diluted loss per share is not presented.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion, or all, of a deferred tax asset will not be realized. The deferred income tax assets were $0 as of both June 30, 2019 and December 31, 2018, respectively.

 

The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires that the Company recognizes deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax basis of assets and liabilities by using enacted tax rates in effect in the years the differences. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when, in the opinion of management, it is more likely than not that some or all of any deferred tax assets will not be realized.

 

Recent Accounting Pronouncements

 

The Company has considered all recent accounting pronouncements issued and their potential effects on its financial statements. The Company's management believes that these recent pronouncements will not have a material effect on the Company's condensed financial statements.

 

NOTE 2. ACCRUED EXPENSES   

 

Accrued expenses consist of the following:

 

 

 

June 30,

2019

 

 

December 31,

2018

 

 

 

(Unaudited)

 

 

 

Accrued professional fees

 

$18,182

 

 

$12,836

 

Accrued edgar agent service fees

 

 

1,222

 

 

 

-

 

Accrued transfer agent fees

 

 

150

 

 

 

2,250

 

Total

 

$19,554

 

 

$15,086

 

 

NOTE 3. DUE TO RELATED PARTIES

 

The Company has received advances from its officers and shareholders for working capital purposes. As of June 30, 2019 and December 31, 2018, there were $213,634 and $183,794 advances outstanding, respectively. The Company has agreed that the outstanding balances bear 0% interest rate and are due upon demand after 30 days written notice by the officer and shareholder.

 

 
8
 
Table of Contents

  

NOTE 4. INCOME TAXES

 

As of June 30, 2019, the Company had net operating loss carryforwards of approximately $491,841 that may be available to reduce future years’ taxable income. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards.

 

The provision for federal income tax consists of the following for the six months ended June 30, 2019 and 2018, respectively:

 

 

 

For the

six months

ended

June 30,

2019

 

 

For the

six months

ended

June 30,

2018

 

Federal income tax benefit attributable to:

 

 

 

 

 

 

Current Operations

 

$7,367

 

 

$10,129

 

Less: valuation allowance

 

 

(7,367)

 

 

(10,129)

Net provision for Federal income taxes

 

$-

 

 

$-

 

 

The tax effects of temporary differences and carryforwards that give rise to significant portions of deferred tax assets and liabilities consist of the following as of June 30, 2019 and December 31, 2018, respectively:

 

 

 

June 30,

2019

 

 

December 31,

2018

 

Deferred tax asset attributable to:

 

(Unaudited)

 

 

 

 

Net operating loss carryover

 

$103,287

 

 

$95,920

 

Less: valuation allowance

 

 

(103,287)

 

 

(95,920)

Net deferred tax asset

 

$-

 

 

$-

 

 

The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below:

 

 

 

For the

six months

ended

June 30,

2019

 

 

For the

six months

ended

June 30,

2018

 

 

 

 

 

 

 

 

Statutory federal tax benefit

 

 

(21)%

 

 

(21)%

Permanent items

 

 

-

 

 

 

-

 

Change in deferred tax asset valuation allowance

 

 

21%

 

 

21%

Provision for income taxes

 

 

-

 

 

-

 

For the six months ended June 30, 2019 and 2018, the Company had no unrecognized tax benefits and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.

 

NOTE 5. SUBSEQUENT EVENT

 

Management has evaluated subsequent events through the date which the financial statements are available to be issued. All subsequent events requiring recognition as of June 30, 2019 have been incorporated into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”

 

******

 

 
9
 
Table of Contents

 

Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operation.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q, including this discussion and analysis by management, contains or incorporates forward-looking statements. All statements other than statements of historical fact made in report are forward looking. In particular, the statements herein regarding industry prospects and future results of operations or financial position are forward-looking statements. These forward-looking statements can be identified by the use of words such as believes, estimates, could, possibly, probably, anticipates, projects, expects, may, will, or should or other variations or similar words. No assurances can be given that the future results anticipated by the forward-looking statements will be achieved. Forward-looking statements reflect management s current expectations and are inherently uncertain. Our actual results may differ significantly from management s expectations.

 

The following discussion and analysis should be read in conjunction with our financial statements, included herewith. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future. Such discussion represents only the best present assessment of our management.

 

Going Concern

 

Our auditor has indicated in their report on our financial statements for the fiscal year ended December 31, 2018, that conditions exist that raise substantial doubt about our ability to continue as a going concern due to our recurring losses from operations, deficit in equity, and the need to raise additional capital to fund operations. A going concern opinion could impair our ability to finance our operations through the sale of debt or equity securities.

 

We require additional funding to meet its ongoing obligations and to fund anticipated operating losses. Our auditor has expressed substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent on raising capital to fund its initial business plan and ultimately to attain profitable operations. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

 

We expect to incur marketing and professional and administrative expenses as well expenses associated with maintaining our filings with Securities and Exchange Commission. We will require additional funds during this time and will seek to raise the necessary additional capital. If we are unable to obtain additional financing, we may be required to reduce the scope of our business development activities, which could harm our business plans, financial condition and operating results. Additional funding may not be available on favorable terms, if at all. We intend to continue to fund its business by way of equity or debt financing and advances from related parties. Any inability to raise capital as needed would have a material adverse effect on our business, financial condition and results of operations.

 

If we cannot raise additional funds, we will have to cease business operations. As a result, our common stock investors would lose all of their investment.

 

Results of Operations

 

Three months ended June 30, 2019 compared to the three months ended June 30, 2018

 

Net revenue: We did not generate any revenue for the three months ended June 30, 2019 and 2018. We have had limited business operations since our inception.

 

General and administrative expenses: General and administrative expenses primarily consist of legal and professional service fees. General and administrative expenses were $14,473 for the three months ended June 30, 2019, as compared to $18,288 for the three months ended June 30, 2018, which represented a decrease of $3,815, or (21)%. The decrease in those expenses was primarily attributable to the decrease in accounting, legal and professional fees.

 

 
10
Table of Contents

 

Other income: Other income mainly consists of interest income. Other income was $0 for the three months ended June 30, 2019, as compared to $2 for the same period last year, representing a decrease of $2, or (100)%. The decrease was not considered a substantial change.

 

Net loss: Our net loss was $14,473 for the three months ended June 30, 2019, as compared to $18,286 for the three months ended June 30, 2018, which represented a decrease of $3,813, or (21)%. The decrease was a result of the decrease in general and administrative expenses.

 

Six months ended June 30, 2019 compared to the six months ended June 30, 2018

 

Net revenue: We did not generate any revenue for the six months ended June 30, 2019 and 2018. We have had limited business operations since our inception.

 

General and administrative expenses: General and administrative expenses primarily consist of legal and professional service fees. General and administrative expenses were $35,080 for the six months ended June 30, 2019, as compared to $48,234 for the six months ended June 30, 2018, which represented a decrease of $13,154, or (27)%. The decrease in general and administrative expenses was primarily attributable to the decrease in accounting, legal and professional fees.

 

Other income: Other income mainly consists of interest income. Other income was $0 for the six months ended June 30, 2019, as compared to $2 for the six months ended June 30, 2018, representing a decrease of $2, or (100)%. The decrease was not considered a substantial change.

 

Net loss: Our net loss was $35,080 for the six months ended June 30, 2019, as compared to $48,232 for the six months ended June 30, 2018, which represented a decrease of $13,152, or (27)%. The decrease in net loss was a result of the decrease in general and administrative expenses.

 

Liquidity and Capital Resources

 

Cash and cash equivalents were $1,347 at June 30, 2019 and $1,197 at December 31, 2018. Our total current assets were $1,347 at June 30, 2019, as compared to $2,119 at December 31, 2018. Our total current liabilities were $233,188 at June 30, 2019, as compared to $198,880 at December 31, 2018.

 

We had negative working capital of $231,841 at June 30, 2019, compared to negative working capital of $196,761 at December 31, 2018. The increase in negative working capital was primarily due to the increase in due to related parties.

 

Net cash provided by operating activities was $150 during the six months ended June 30, 2019, compared to $2 during the six months ended June 30, 2018. The increase in the cash provided by operating activities was primarily due to the decreased net loss and due to related parties, partially offset by the increase in accrued expenses.

 

We had no net cash flow from investing activities and financing activities during the six months ended June 30, 2019 and 2018.

 

Net change in cash and cash equivalents was an increase of $150 during the six months ended June 30, 2019, compared to an increase of $2 during the six months ended June 30, 2018.

 

Critical Accounting Policies

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ( U.S. GAAP ) requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities in the financial statements and accompanying notes. The SEC has defined a company s critical accounting policies as the ones that are most important to the portrayal of the company s financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have not identified any additional critical accounting policies and judgments. We also have other key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding our results, which are described in the Note 1 to our financial statements. Although we believe that our estimates, assumptions and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments or conditions.

 

 
11
Table of Contents

 

Off-balance Sheet Arrangements

 

As of June 30, 2019, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current of future effect on our financial conditions, changes in financial conditions, revenues or expenses, results of operations, liquidity capital expenditures, or capital resources that is material to investors.

 

Recent Accounting Pronouncements

 

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of any such pronouncements may be expected to cause a material impact on its financial condition or the results of its operations.

 

Inflation

 

Our opinion is that inflation has not had a material effect on our operations and is not expected to have any material effect on our operations.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

 

As a smaller reporting company, we are not required to provide this information.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures designed to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC s rules and forms, and that the information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. We performed an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on their evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were not effective as of June 30, 2019.

 

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures is also based partially on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Changes in Internal Control Over Financial Reporting

 

There have been no changes in our internal controls over financial reporting that occurred during our last fiscal quarter to which this Quarterly Report on Form 10-Q relates that have materially affected, or are reasonably likely to materially affect our internal controls over financial reporting.

 

 
12
 
Table of Contents

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

None.

 

Item 1A. Risk Factors.

 

As a smaller reporting company, we are not required to provide this information.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None in the three months ended June 30, 2019.

 

Item 3. Defaults upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

 
13
 
Table of Contents

 

Item 6. Exhibits.

 

The following exhibits are filed as part of this quarterly report, pursuant to Item 601 of Regulation S-K. All exhibits are attached hereto unless otherwise noted.

 

Exhibit Number

 

Description

 

31.1 *

 

Certification of Principal Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

31.2 *

 

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

32.1 *

 

Certification of the Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 906 of the Sarbanes-Oxey Act of 2002

 

32.2 *

 

Certification of the Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, Pursuant to Section 906 of the Sarbanes-Oxey Act of 2002

 

101.INS

 

XBRL Instance Document

 

101.SCH

 

XBRL Taxonomy Extension Schema Document

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

 

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document

____________

* Filed herewith

 

 
14
 
Table of Contents

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Lazuriton Nano Biotechnology (U.S.A.) Inc.

 

Date: August 26, 2019

By:

/s/ Chih-Yuan Hsiao

 

Chih-Yuan Hsiao

 

 

Principal Executive Officer

 

 

15